The companion diagnostics of targeted therapy and immunotherapy for hepatocellular carcinoma.
10.3760/cma.j.cn501113-20220716-00383
- Author:
Xiao Wen HUANG
1
;
Shu Hong LIU
1
;
Jing Min ZHAO
1
Author Information
1. Department of Pathology and Hepatology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Carcinoma, Hepatocellular/pathology*;
Liver Neoplasms/pathology*;
Immunotherapy;
Antineoplastic Agents/therapeutic use*;
Molecular Targeted Therapy
- From:
Chinese Journal of Hepatology
2022;30(9):912-917
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) has a high incidence and low five-year survival rate in China. There is a lack of effective therapeutic approaches available for unresectable patients with advanced HCC. Recently, the development of targeted and immunotherapy agents and their application in the therapy of various solid tumors have brought new options and benefits to patients with advanced HCC. Companion diagnostics (CDx) emerged with the development of targeted agents, and its roles in selecting eligible patients for specific targeted/immunotherapy agents and improving prognosis are getting more prominent. This article focuses on the CDx technologies and applications related to HCC targeting and immunotherapy, in order to provide inspiration for the precise diagnosis and treatment of HCC.
